Keros Therapeutics Inc
NASDAQ:KROS

Watchlist Manager
Keros Therapeutics Inc Logo
Keros Therapeutics Inc
NASDAQ:KROS
Watchlist
Price: 10.79 USD -1.82% Market Closed
Market Cap: 437.6m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one KROS stock under the Base Case scenario is 4.5 USD. Compared to the current market price of 10.79 USD, Keros Therapeutics Inc is Overvalued by 58%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KROS Relative Value
Base Case
4.5 USD
Overvaluation 58%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

123.3
P/S
P/S
Price to Sales
123.3
vs History
49
vs Industry
13
Median 3Y
71
Median 5Y
125.6
Industry
7
Forward
105.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-11.7
Median 5Y
-14.3
Industry
21.5
Forward
-3.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-13.7
Median 5Y
-17.6
Industry
20
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-13.4
Median 5Y
-17.3
Industry
25.4
More Details
0.8
P/B
P/B
Price to Book Value
0.8
vs History
96
vs Industry
64
Median 3Y
4
Median 5Y
4.4
Industry
2.4
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
1
Median 3Y
51.9
Median 5Y
58.4
Industry
7.3
Forward
-29.5
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.3
More Details
0.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
0.6
vs History
0
vs Industry
24
Median 3Y
-8.2
Median 5Y
-9.8
Industry
4
Forward
0.6
More Details
0.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
0.6
vs History
0
vs Industry
22
Median 3Y
-8.2
Median 5Y
-9.7
Industry
3.8
Forward
0.7
More Details
0.8
EV/OCF
EV/OCF
Enterprise Value to OCF
0.8
vs History
0
vs Industry
24
Median 3Y
-10.3
Median 5Y
-13.2
Industry
4.9
More Details
0.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
0.8
vs History
0
vs Industry
20
Median 3Y
-10.1
Median 5Y
-13
Industry
3.3
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
8
Median 3Y
41.7
Median 5Y
50.1
Industry
4.3
More Details

Multiples Across Competitors

KROS Competitors Multiples
Keros Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Keros Therapeutics Inc
NASDAQ:KROS
437.6m USD 123.3 -2.3 0.6 0.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 631 037.3 -174 101.9 -211 415.2 -209 002.7
US
Abbvie Inc
NYSE:ABBV
369.9B USD 6.6 87.3 17.1 25.7
US
Amgen Inc
NASDAQ:AMGN
167.8B USD 5 40.9 16.5 29.3
US
Gilead Sciences Inc
NASDAQ:GILD
139.7B USD 4.9 290.9 11.4 14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.2B USD 11.3 -232.6 25.3 26.5
US
Epizyme Inc
F:EPE
94.1B EUR 1 923.2 -490.7 -534.4 -520.2
AU
CSL Ltd
ASX:CSL
120.7B AUD 5 27.6 17 21.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
69.4B USD 4.9 15.8 10.1 11.3
US
Seagen Inc
F:SGT
39.3B EUR 18.5 -56.8 -61.1 -55.1
NL
argenx SE
XBRU:ARGX
32.3B EUR 16 42 309.5 -2 279.9
P/S Multiple
Revenue Growth P/S to Growth
US
Keros Therapeutics Inc
NASDAQ:KROS
Average P/S: 3 330 286.9
123.3
93%
1.3
FR
Pharnext SCA
OTC:PNEXF
36 631 037.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.3
10%
1.1
US
E
Epizyme Inc
F:EPE
1 923.2
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.9
7%
0.7
US
S
Seagen Inc
F:SGT
18.5
30%
0.6
NL
argenx SE
XBRU:ARGX
16
37%
0.4
P/E Multiple
Earnings Growth PEG
US
Keros Therapeutics Inc
NASDAQ:KROS
Average P/E: 84.1
Negative Multiple: -2.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -174 101.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.3
87%
1
US
Amgen Inc
NASDAQ:AMGN
40.9
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
290.9
187%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -232.6 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -490.7 N/A N/A
AU
CSL Ltd
ASX:CSL
27.6
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.8
12%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.8 N/A N/A
NL
argenx SE
XBRU:ARGX
42
26%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Keros Therapeutics Inc
NASDAQ:KROS
Average EV/EBITDA: 50.9
0.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -211 415.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.1
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.5
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11.4
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.3
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.1
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.1 N/A N/A
NL
argenx SE
XBRU:ARGX
309.5
166%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Keros Therapeutics Inc
NASDAQ:KROS
Average EV/EBIT: 18.4
0.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 002.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.7
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.3
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -520.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.3
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.3
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 279.9 N/A N/A

See Also

Summary
KROS intrinsic value, competitors valuation, and company profile.
DCF Valuation
KROS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KROS stock valuation using valuation multiples.
Wall Street Estimates
KROS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KROS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 242,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.